its a good model, to put the equity raising on this separate venture, for this expansion process to china.
So it costs us nothing in dilution, but we essentially vend in the IP, for a 30% stake in this door way.
The more door ways that open for us to china, the market will wake up to the increasing scale of the prize.
Ann: MOU with Temasek-linked Innoventures - Orthopaedics in China, page-7
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
